MAR 14, 2016 12:34 PM PDT

Drug Duo Dramatically Shrunk Breast Tumors in 11 Days

WRITTEN BY: Xuan Pham
In a ground-breaking “surprise” finding, UK doctors announced a pair of drugs dramatically shrunk some breast tumors in a mere 11 days after diagnosis. The results were publicly presented at the European Breast Cancer Conference, and could have wide-reaching impacts for the treatment of breast cancers.
 
New tailored treatments for HER2 positive breast cancers on the horizon

The study was conducted to explore how drugs alter breast cancer biology in the short time between diagnosis and surgical resection. The 257 women recruited for the study were diagnosed with human epidermal growth factor receptor 2, otherwise known as HER2-positive, breast cancer. For some women who were treated with both trastuzumab (Herceptin) and lapatinib (Tyverb), doctors found little to no trace of the breast tumors when it came time to operate at day 11. The results were so remarkable that it surprised even the study surgeons, who didn’t expect to achieve such results in such a short amount of time.

"This has ground-breaking potential because it allows us to identify a group of patients who, within 11 days, have had their tumors disappear with anti-HER2 therapy alone and who potentially may not require subsequent chemotherapy," said Nigel Bundred, chief investigator and surgical oncology professor at the University of Manchester. "This offers the opportunity to tailor treatment for each individual woman."

The study included 127 women who were either given trastuzumab only, both trastuzumab and lapatinib, or no drugs at all. For women who took the drug duo, researchers found 87 percent had significant decrease in the number of cancer cells. Remarkably, 11 percent of these women had no active cancer cells at all. Another 17 percent showed marked reduction in tumor size from 1 to 3 centimeters to less than 5 millimeters in diameter.

The drugs are not new and they both target the HER2 protein. Herceptin is known to work on the surface of cancer cells while lapatinib penetrates inside the cell to disable HER2. As part of current treatment for HER2 positive breast cancer, surgery is the first step, followed by chemotherapy with Herceptin.

These results suggest that some patients may not need chemotherapy if the drugs are administered quickly enough after diagnosis. It may also recalibrate how quickly doctors can assess response in patients after treatment, as this study revealed it can be done in as short as 11 days.

However, the doctors are cautiously optimistic, noting that these astonishing results need to be confirmed in more trials. Given that HER2 positive breast cancers have a high penchant for recurring, the additional trials are absolutely vital to establish whether or not chemotherapy can be skipped. "We would have to be very clear we're not taking a backwards step and increasing the risk of relapse," said Judith Bliss, co-investigator of the study.
 

Additional source: European Cancer Organization
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
DEC 05, 2019
Cancer
DEC 05, 2019
The golden future of cancer treatment
A study published recently in Chemistry -- A European Journal features research on the golden cancer treatments of the future – literally. Current me...
DEC 05, 2019
Drug Discovery & Development
DEC 05, 2019
Leukemia Drug Effective for Treating Childhood Brain Cancer
Scientists at the University of California-San Diego have found that a chronic myeloid leukemia drug was found to treat medulloblastoma in mouse models mor...
DEC 05, 2019
Genetics & Genomics
DEC 05, 2019
How Liquid Biopsies Can Teach Us About Cancer Drug Resistance
Cancer patients often endure challenging treatment courses to shrink their tumors, but the tumors can make a powerful comeback....
DEC 05, 2019
Genetics & Genomics
DEC 05, 2019
A Cancer-Promoting Mutation is Found in 'Junk' DNA
A huge amount of our genome does not code for protein, but it can impact physiology in other ways....
DEC 05, 2019
Cancer
DEC 05, 2019
An astronaut's training for cancer patients
The comparison is perhaps unexpected, but the findings show potential: astronauts experience similar physical stress in spaceflight as cancer patients rece...
DEC 05, 2019
Cancer
DEC 05, 2019
Photon up-conversion for new cancer treatments
Scientists from the University of California, Riverside and The University of Texas at Austin have made a breakthrough in materials science that has signif...
Loading Comments...